Century Therapeutics Q3 2026: Cash Runway, Narrowing Losses, and a Diabetes IND on Deck

Century Therapeutics met expectations in the third quarter of 2026, but the more important story is how much smaller the losses are becoming. Net loss narrowed to $23.45 million, a meaningful improvement driven by lower R&D spending and the absence of an asset impairment charge that weighed on Q3 2025.

R&D expenses fell to $18.06 million, reflecting a deliberate portfolio prioritization that reduced both personnel and facility costs. That discipline is allowing the company to do more with less as it approaches two clinical inflection points, without burning through the cash that underpins its entire operating strategy.

The company ended September with $174.1 million in cash, cash equivalents, and investments. Management says that runway extends into the first quarter of 2029, a figure that stands out because it represents more than half of Century's total market capitalization, an unusually strong buffer for a pre-revenue biotech.

The nearer-term catalyst is the planned IND submission for CNTY-813, an iPSC-derived islet replacement therapy targeting type 1 diabetes, expected this quarter. CEO Brent Pfeiffenberger noted that the FDA has provided general alignment on the nonclinical package, the Phase 1 manufacturing process, and the Phase 1/2 trial design following a pre-IND meeting, reducing a key regulatory uncertainty ahead of the filing.

If the IND clears, Century anticipates initial safety and early efficacy data from the first-in-human study in the second half of 2027. The company's other lead program, CNTY-308, a CD19 CAR-iT cell therapy, is also expected to enter the clinic in 2026. Management has characterized 2027 as a transition to clinical execution, meaning the next several quarters carry unusual binary weight for the stock.